GENE THERAPEUTIC VECTOR DEVELOPMENT
Similar Organizations
BindView Development
BindView Development
Cenvill Development
Cenvill Development
Defensin Therapeutics ApS
Defensin Therapeutics ApS
Diamond Therapeutics
Diamond Therapeutics is a psychedelic drug development company.
SanoGene Therapeutics
SanoGene Therapeutics is a biotechnology company that develops biopharmaceutical.
More informations about "Gene Therapeutic Vector Development"
Top 23 Pioneers in Viral Vector Gene Therapy
Home - 5th Next Generation Gene Therapy Vectors 2025
2024 saw huge investments in gene therapy vectors. Following a $1.1 billion acquisition of Kate Therapeutics by Novartis and a collaboration between Roche and Dyno Therapeutics, which …See details»
Azenta Life Sciences and Form Bio Announce Strategic …
2 days ago Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a ...See details»
Gene Therapy Vector Facility (GTVF) - King's College …
The King’s College London Gene Therapy Vector Facility (GTVF) is a state-of-the-art facility established to support early-stage clinical trials with GMP-grade viral vector as drug substance or drug product. With a legacy dating back to …See details»
Viralgen completes glioblastoma gene-therapy batch production …
4 hours ago Contract development manufacturing organization (CDMO) Viralgen has successfully scaled up material for Trogenix’s recombinant adeno-associated virus (rAAV) …See details»
The Future of AAV Gene Therapy: Advances in Viral …
Jun 14, 2024 Manufacturing these viral vectors, however, is a complex and critical component in the success of gene therapy. The expert team at Genezen, a leading AAV Contract Development and Manufacturing Organization …See details»
One viral vector partner for every gene therapy development
Viral vector gene therapies have the potential to treat a diverse array of diseases that were once considered untreatable. From genetic disorders to rare cancers and infectious diseases, viral …See details»
The tale of two companies: One viral vector partner for …
May 6, 2024 Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene therapy technology becomes more advanced, producing viral vectors becomes ...See details»
Hovione and Firstgene announce strategic collaboration to …
Lisbon, Portugal, May 6, 2025 – Hovione, an international integrated pharmaceutical development and manufacturing organization, and Firstgene Life Sciences, a portfolio company of the Swiss …See details»
A CDMO partner for every gene therapy manufacturing stage
Feb 9, 2024 From early innovations to commercial triumphs: One viral vector partner for every stage of gene therapy development. Gene therapies harness the transformative power to …See details»
Lentivirus Vector Platform - Lentivation™ | Charles River
Sep 29, 2023 Lentiviral vector platform enables a cost-effective and reliable path to GMP in less than seven months. Leveraging decades of viral vector contract development and …See details»
Vertex discontinues AAV vector research for gene therapies
May 2, 2025 Meanwhile, Roche recently unveiled a “fundamental reorganization” of the company’s gene therapy unit Spark Therapeutics, in a move that will cost the Swiss pharma …See details»
Viral Vector Systems for Gene Therapy: A Comprehensive …
Second, the development of gutless adenoviral vectors allows us to circumvent antiadenoviral vector immunity. 63 The AV vector now represents 1 of the 3 major viral vector categories in …See details»
Adeno-Associated Virus Gene Therapy Development: Early
Feb 20, 2025 The Platform Vector Gene Therapy (PaVe-GT) program is a National Institutes of Health (NIH) initiative developing adeno-associated virus (AAV) gene therapies for four low …See details»
Viral-vector therapies at scale: Today’s challenges and future ...
Mar 29, 2022 Viral-vector research and funding are currently directed toward the accelerated development of high-yield producer cell lines, which would enable higher-quality and more …See details»
AGC Biologics Partners with Quell Therapeutics to Advance T …
3 hours ago The AGC Biologics Milan Cell and Gene Center of Excellence offers 30 years of experience in cell and gene therapy, with nine commercial approvals and hundreds of GMP …See details»
Process Development and Manufacturing Avenues for Gene …
Sep 30, 2022 Hemant Dhamne is the head of their process development team and is an expert in cell and gene therapy. Speaking at Oxford Global's Gene Therapy Development …See details»
Recommended Stories
14 hours ago SEATTLE & MILAN, May 15, 2025--AGC Biologics supports the development of multiple Treg cell therapy drug candidates targeting severe immune disorders for Quell …See details»
Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects …
Genomic organization of the adenovirus and its vector derivatives. A schematic representation of the wild-type adenovirus genome and its transcription units is shown on top (A).The double …See details»
Redefining AAV Quality Control in Cell and Gene Therapy …
Apr 14, 2025 Improving the therapeutic quality and consistency of cell and gene therapies requires the adoption of enhanced Critical Quality Attributes (CQAs) throughout the …See details»